Shares of Nuvalent, Inc. were surging around 39 percent in the pre-market activity on the Nasdaq, after the clinical-stage biopharma company focused on cancer therapies agreed to be acquired by British drug major GSK plc, in a deal valued at $10.6 billion or 8.0 billion pounds. Further, GSK maintained its 2026 guidance range of 7 percent to 9 percent growth in core operating profit and core EPS.
Caris Life Sciences (CAI), an AI TechBio company, Monday announced that it has been authorized to repurchase up to $100 million of the company's outstanding common stock. The timing, manner, price, and amount of any repurchases will be determined at the Company's discretion based on a variety of factors,...
Monday, Standard BioTools Inc. (LAB) announced an agreement with Treeline Biosciences, Inc., a clinical-stage biopharma company, to combine in an all-stock transaction. The transaction values Standard BioTools at net cash delivered at closing, plus $10 million, which is estimated to be $460 million....
Johnson & Johnson (JNJ) on Monday announced a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company for $1 billion in cash. The transaction is expected to close later this year. The acquisition is expected to expand Johnson & Johnson's oncology pipeline with Firefly Bio's...
Bavarian Nordic A/S (BAVA.CO), a vaccine developer, on Tuesday announced the award of a government contract valued at more than DKK 700 million to supply its MVA-BN smallpox/mpox vaccine to an undisclosed country. Deliveries under the contract are scheduled to take place in 2026 and 2027. The company...
GSK plc (GSK, GSK.L) has entered an agreement to acquire Nuvalent, Inc. (NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies, for $10.6 billion. The company noted that the acquisition includes three products in lung cancer in a single transaction....
Tuesday, TG Therapeutics, Inc. (TGTX) announced positive topline Phase 1 data for BRIUMVI in patients with myasthenia gravis, a chronic autoimmune neuromuscular disease. At Week 24, 82 per cent of patients who received BRIUMVI achieved the Minimal Clinically Important Difference in MG-ADL, with a...
Monday, Tango Therapeutics, Inc. (TNGX) announced positive initial data from its ongoing Phase 1/2 study of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors daraxonrasib or zoldonrasib. During the study, patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal...
Fractyl Health, Inc. (GUTS), a clinical-stage metabolic therapeutics company, on Thursday announced positive one-year results for Revita from its REVEAL-1 Cohort study. Revita is the company's lead product candidate, designed to remodel the duodenal lining of the small intestine through a one-time,...
argenx SE (ARGX), an immunology company, on Wednesday reported positive data for efgartigimod in autoimmune rheumatic diseases, including myositis and Sjogren's disease, ahead of presentations at the EULAR 2026 Congress in London. In the ongoing ALKIVIA+ extension study in myositis, patients who continued...
RedHill Biopharma Ltd. (RDHL) announced the FDA has granted rare pediatric disease designation to opaganib for treatment of neuroblastoma. The rare pediatric disease designation to opaganib provides for a Priority Review Voucher, subject to certain conditions. Opaganib has received Orphan Drug designation...
June's FDA calendar offers plenty for investors to keep a close eye on. Among the key names are Spero Therapeutics, awaiting an FDA decision on its antibiotic for complicated urinary tract infections; Kiniksa Pharma, seeking approval for a technology transfer of the manufacturing process for Arcalyst drug substance; and Merck, pursuing the first FDA approval for its WELIREG - KEYTRUDA combination.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
Retailer Target Corp. is recalling select Up & Up Baby Wipes, due to potential microbial contamination, according to the U.S. Food and Drug Administration. The recall involves Up & Up FragranceFree Baby Wipes and Up & Up Fresh Cucumber Scented Baby Wipes with various counts and UPC numbers. The impacted wipes were manufactured by a supplier, Sapro Temizlik Urunleri, and sold at Target stores...
a2 Milk Company Ltd. (ACOPF, A2M.AX), a dairy company, announced a recall of select infant milk formula, manufactured by Synlait Milk Limited and sold only in the United States, citing the presence of cereulide. The recall involves three batches of a2 Platinum USA label infant milk formula, comprising...
the CRL for its NDA of bitopertin in erythropoietic protoporphyria (EPP). The company confirmed alignment with the FDA that the ongoing Phase 3 APOLLO study, if successful, can serve as the basis for a CRL response and potentially support a traditional approval.
Giving babies eggs early in life may help reduce their risk of developing egg allergies, especially for infants with eczema, according to a new study. The study, conducted by researchers from The University of Queensland and Murdoch Children's Research Institute, analyzed data from more than 7,200...
Chinese researchers have carried out the world's first transplant of two pig kidneys and a pig liver into a 53-year-old brain-dead man at the same time, marking an important step forward in xenotransplantation. The surgery was conducted at the Second Affiliated Hospital of Guangxi Medical University...
The Africa Centres for Disease Control and Prevention (Africa CDC) and the World Health Organization (WHO) have launched a joint plan to help African countries prepare for and respond to the ongoing Ebola outbreak caused by the Bundibugyo virus. The joint initiative comes as authorities in the Democratic...
Cullinan Therapeutics Inc. (CGEM), a clinical-stage biopharmaceutical company, is scheduled to host an Immunology Day tomorrow, i.e., June 10, 2026. When we alerted readers to CGEM on June 29, 2025, it was at $7.93. The stock, which touched a high of $16.74 on February 27, 2026, has given back some of its gains and currently trades around $13.